# Working With Alimentiv

Leveraging 30+ years of global experience and expertise in GI clinical trials, **Alimentiv** has an unparalleled understanding of the GI therapeutic landscape and current practices.

Our established partnerships and scientific leadership make us the trusted CRO for full-service GI clinical trials.

# Monitoring & Site Management Track Record

**We provide global monitoring services, delivered by seasoned GI monitoring experts:**

- Average CRA experience: **10+ years**
- Extensive GI training
- Low CRA turnover rates

## Alimentiv's Therapeutic Focus

Alimentiv stands at the forefront of patient recruitment and imaging innovations for gastrointestinal and liver diseases. We drive health breakthroughs by advancing research, accelerating clinical trials, and delivering actionable biomarker insights.

## Key Indications

- **Inflammatory bowel disease (IBD):** Ulcerative colitis (UC) and Crohn's disease (CD), fibrostenosing Crohn's disease, pouchitis
- **Eosinophilic gastrointestinal diseases (EGIDs):** Eosinophilic esophagitis (EoE)
- **Microscopic colitis**
- **Celiac disease (CeD)**
- **Functional and motility disorders of the gastrointestinal tract:** Gastroparesis
- **Familial adenomatous polyposis (FAP)**
- **Inflammatory liver conditions:** Primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC)

Contact us to learn more or to partner with our Global Site Network
**asn@alimentiv.com**

alimentiv™


**Canada**
800 Collip Circle
Suite 104 London, Ontario
Canada N6G 4X8

**USA**
6220 Greenwich Dr.
Suite 101, San Diego
California, USA 92122

**Europe**
Hullenbergweg 278-308
Vogelstruys Building
1101 BV Amsterdam

**Australia**
Suite 6, Level 2
29-31 Lexington Drive
Bella Vista NSW 2153


alimentiv™

# Partner With Our Global Site Network

alimentiv.com/site-network

# GI IS OUR WHY

**We are a global GI-focused contract research organization (CRO)** providing clinical trial, core medical imaging, precision medicine, and real-world evidence services to pharmaceutical and biotechnology industries.

Our core therapeutic focus includes **inflammatory bowel disease (IBD), eosinophilic gastrointestinal disorders (EGID), celiac disease,** and **liver diseases.**

## We Are Global

With headquarters in **London, ON, Canada,** and 500+ experienced employees across **North America, Europe, LATAM** and **APAC,** we ensure global site coverage and unparalleled support for our sites.

Over the last 5 years, Alimentiv has conducted **35+ full-service GI clinical studies,** spanning phases 1 – 4.

## Full-Service Studies

- Crohn's disease (CD)
- Ulcerative colitis
- Pouchitis
- Fistulizing and fibrostenotic CD
- Pediatric CD
- Hepatic impairment
- Eosinophilic esophagitis
- Renal impairment
- Gastroparesis

## Our Science

Alimentiv is committed to science through:

- Outcomes development
- Design & conduct of Alimentiv-sponsored studies
- Publication & presentation at research meetings
- Participation in scientific consortiums
- Leadership & participation in advisory boards
- Clinical Trial Fellowship program

## Medical R&D Expertise:

**Vipul Jairath, MD**
Chief Medical Officer

**Chris Ma, MD**
Senior Medical Director

**Gabriela Radulescu, MD**
VP, MR&D

**Geert D'Haens, MD**
Scientific Advisor

**Wendy Teft, PhD**
VP, AcelaBio

**Remo Panaccione, MD**
Scientific Advisor

**GY Zou, PhD**
Biostatistician Director

## How We Support Our Sites:

- Hire CRAs and other project team members who are GI clinical trial experts and undergo rigorous ongoing training to ensure **consistency** of knowledge and experience.
- Support project teams with our **expert scientific leaders.**
- Provide training and **follow-up support** for principal investigators and site staff.
- Employ **local experts** familiar with country/language-specific submission processes and regulatory knowledge for each site.
- Support site activities via dedicated and highly **experienced project managers** and **clinical operation leads.**
- Ensure protocols offered to your sites match your interest, experience and capabilities.
- Apply efficiencies in our start-up and overall clinical trial processes to **alleviate the sites' burden.**
- Ensure **long-term relationships** are built between the CRA and site team with low CRA turnover rates.
- Focus on the development of patient and site-centric solutions (e.g. e-diaries and e-consent) to **support our sites** and alleviate the site burden.
- Maintain connection with our sites through regular **in-person** and **online** meetings with the Site Engagement team to keep us informed about the latest developments at your site and in the overall GI clinical trial landscape.